{"id":13886,"date":"2024-09-30T22:17:04","date_gmt":"2024-09-30T22:17:04","guid":{"rendered":"https:\/\/medexperts.pro\/?p=13886"},"modified":"2024-09-30T22:24:05","modified_gmt":"2024-09-30T22:24:05","slug":"cerebras-files-prospectus-for-i-p-o","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=13886","title":{"rendered":"Cerebras Files Prospectus for I.P.O."},"content":{"rendered":"<div><\/div>\n<div class=\"css-s99gbd StoryBodyCompanionColumn\" data-testid=\"companionColumn-0\">\n<div class=\"css-53u6y8\">\n<p class=\"css-at9mc1 evys1bk0\">For two years, stock investors wanting in on the frenzy around artificial intelligence have had only a few tech industry options: big companies like Microsoft and Nvidia. But that is set to change in the coming weeks with the market debut of Cerebras, a <a class=\"css-yywogo\" href=\"https:\/\/www.nytimes.com\/2019\/08\/19\/technology\/artificial-intelligence-chip-cerebras.html\" title>chip company with bold ambitions<\/a> to take on Nvidia.<\/p>\n<p class=\"css-at9mc1 evys1bk0\">Cerebras, based in Sunnyvale, Calif., unveiled its investor prospectus on Monday, taking an important step toward listing its shares on the stock market. In doing so, the start-up aims to break the drought of hot I.P.O.s and take advantage of investor excitement for all things A.I.<\/p>\n<p class=\"css-at9mc1 evys1bk0\">Just 82 companies went public in the United States in the first half of the year, a slight uptick from last year, according to <a class=\"css-yywogo\" href=\"https:\/\/www.ey.com\/en_us\/insights\/ipo\/ipo-market-trends\" title rel=\"noopener noreferrer\" target=\"_blank\">data<\/a> collected by EY. Only 24 of them, including the social network Reddit and the data security company Rubrik, were venture-capital-backed start-ups. In May, Crunchbase News <a class=\"css-yywogo\" href=\"https:\/\/news.crunchbase.com\/startups\/unicorn-startup-exits-ipo-acquisitions-pace-backlog-data\/\" title rel=\"noopener noreferrer\" target=\"_blank\">calculated<\/a> that, at the current pace, it would take 49 years for all private start-ups based in the United States valued at $1 billion or more to go public.<\/p>\n<p class=\"css-at9mc1 evys1bk0\">Even though conditions to go public are good \u2014 interest rates are falling, and tech stocks are trading up \u2014 many companies have pushed I.P.O. plans to 2025, hoping to avoid any market volatility caused by the presidential election.<\/p>\n<\/div>\n<\/div>\n<div data-testid=\"Dropzone-1\"><\/div>\n<div class=\"css-s99gbd StoryBodyCompanionColumn\" data-testid=\"companionColumn-1\">\n<div class=\"css-53u6y8\">\n<p class=\"css-at9mc1 evys1bk0\">\u201cIt\u2019s almost like a wait-and-see type of environment,\u201d said Mark Schwartz, an I.P.O. advisory leader at EY.<\/p>\n<p class=\"css-at9mc1 evys1bk0\">Cerebras would be among the first A.I. companies to go public since <a class=\"css-yywogo\" href=\"https:\/\/www.nytimes.com\/2022\/12\/10\/technology\/ai-chat-bot-chatgpt.html\" title>OpenAI released its ChatGPT<\/a> chatbot in late 2022. Tempus A.I., a health care company, and Astera Labs, a semiconductor company, both listed their shares this year.<\/p>\n<div class=\"css-1336jj\">\n<div class=\"css-121kum4\">\n<div class=\"css-171d1bw\"><\/div>\n<div class=\"css-asuuk5\">\n<div class=\"css-7axq9l\" data-testid=\"optimistic-truncator-noscript\">\n<div data-testid=\"optimistic-truncator-noscript-message\" class=\"css-6yo1no\">\n<p class=\"css-3kpklk\">We are having trouble retrieving the article content.<\/p>\n<p class=\"css-3kpklk\">Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n<div class=\"css-1dv1kvn\" id=\"optimistic-truncator-a11y\">\n<hr \/>\n<p>Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0<a href=\"https:\/\/myaccount.nytimes.com\/auth\/login?response_type=cookie&amp;client_id=vi&amp;redirect_uri=https%3A%2F%2Fwww.nytimes.com%2F2024%2F09%2F30%2Ftechnology%2Fcerebras-ai-chips-ipo.html&amp;asset=opttrunc\">log into<\/a>\u00a0your Times account, or\u00a0<a href=\"https:\/\/www.nytimes.com\/subscription?campaignId=89WYR&amp;redirect_uri=https%3A%2F%2Fwww.nytimes.com%2F2024%2F09%2F30%2Ftechnology%2Fcerebras-ai-chips-ipo.html\">subscribe<\/a>\u00a0for all of The Times.<\/p>\n<hr \/>\n<\/div>\n<div class=\"css-1g71tqy\">\n<div data-testid=\"optimistic-truncator-message\" class=\"css-6yo1no\">\n<p class=\"css-3kpklk\">Thank you for your patience while we verify access.<\/p>\n<p class=\"css-3kpklk\">Already a subscriber?\u00a0<a data-testid=\"log-in-link\" class=\"css-z5ryv4\" href=\"https:\/\/myaccount.nytimes.com\/auth\/login?response_type=cookie&amp;client_id=vi&amp;redirect_uri=https%3A%2F%2Fwww.nytimes.com%2F2024%2F09%2F30%2Ftechnology%2Fcerebras-ai-chips-ipo.html&amp;asset=opttrunc\">Log in<\/a>.<\/p>\n<p class=\"css-3kpklk\">Want all of The Times?\u00a0<a data-testid=\"subscribe-link\" class=\"css-z5ryv4\" href=\"https:\/\/www.nytimes.com\/subscription?campaignId=89WYR&amp;redirect_uri=https%3A%2F%2Fwww.nytimes.com%2F2024%2F09%2F30%2Ftechnology%2Fcerebras-ai-chips-ipo.html\">Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>For two years, stock investors wanting in on the frenzy around artificial intelligence have had only a few tech industry options: big companies like Microsoft and Nvidia. But that is set to change in the coming weeks with the market debut of Cerebras, a chip company with bold ambitions to take on Nvidia.Cerebras, based in Sunnyvale, Calif., unveiled its investor prospectus on Monday, taking an important step toward listing its shares on the stock market. In doing so, the start-up aims to break the drought of hot I.P.O.s and take advantage of investor excitement for all things A.I.Just 82 companies went public in the United States in the first half of the year, a slight uptick from last year, according to data collected by EY. Only 24 of them, including the social network Reddit and the data security company Rubrik, were venture-capital-backed start-ups. In May, Crunchbase News calculated that, at the current pace, it would take 49 years for all private start-ups based in the United States valued at $1 billion or more to go public.Even though conditions to go public are good \u2014 interest rates are falling, and tech stocks are trading up \u2014 many companies have pushed I.P.O. plans to 2025, hoping to avoid any market volatility caused by the presidential election.\u201cIt\u2019s almost like a wait-and-see type of environment,\u201d said Mark Schwartz, an I.P.O. advisory leader at EY.Cerebras would be among the first A.I. companies to go public since OpenAI released its ChatGPT chatbot in late 2022. Tempus A.I., a health care company, and Astera Labs, a semiconductor company, both listed their shares this year.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":13888,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-13886","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/13886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13886"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/13886\/revisions"}],"predecessor-version":[{"id":13889,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/13886\/revisions\/13889"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/13888"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}